Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness
Drug: Measles-Mumps-Rubella Vaccine
Measles mumps Rubella vaccine is a weak attenuated life vaccine
Drug: Placebos
0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
Inclusion Criteria:
- Age 18-50 years old
- Subjects who are willing to comply with the requirements of the study protocol and
scheduled visits (for example, completion of the subject diary, return for follow-up
visits) and who are willing to make themselves available for the duration of the study
with access to a consistent means of telephone contact
Exclusion Criteria:
- acute severe illness
- recent receipt of a blood product
- history of thrombocytopenia
- Pregnant females
- any chronic medical condition
- Any participant receiving any immune suppressive medication
- Immunocompromised staff
- Participants who have egg allergy
- Participants who care for immune compromised hosts
- Participants who test positive for COVID-19 serology prior to randomization
Cairo University Hospital
Cairo, Egypt